Tesamorelin Dosage: Daily Clarity, Two Formulations

Tesamorelin dosage is actually straightforward: a once-daily abdominal injection. The real distinction is the formulation. EGRIFTA SV and EGRIFTA WR both work once daily, but the mixing routines, vial strengths, and storage rules are different—and those details matter.

How tesamorelin dosing actually works

EGRIFTA SV calls for 1.4 mg once daily, delivered as 0.35 mL after mixing one 2 mg vial with 0.5 mL sterile water each day. EGRIFTA WR is 1.28 mg once daily, delivered as 0.16 mL after mixing one 11.6 mg vial with 1.3 mL bacteriostatic water once a week—one vial covers seven consecutive days. These formulations are not interchangeable; your pharmacy will dispense one or the other, and the mixing steps are distinct.

• EGRIFTA SV: 1.4 mg once daily, single-use daily reconstitution, inject immediately after mixing.
• EGRIFTA WR: 1.28 mg once daily, one weekly reconstitution, one vial supplies all seven daily doses.
• Both are abdominal injections with site rotation. The formulation determines your entire mixing and storage routine.

Why the indication is what makes tesamorelin precise

Here is what separates tesamorelin from broader weight-loss compounds. Both current labels are specifically for reducing excess abdominal fat in adults with HIV lipodystrophy, and both explicitly state that tesamorelin is not indicated for weight loss management. That puts it in a different lane from tirzepatide or semaglutide, where the entire treatment frame centers on obesity and appetite control. Tesamorelin is more specialized—and that precision is actually what makes its protocol clear.

The evidence is stronger than you might expect

The strongest tesamorelin data come from rigorous HIV-associated abdominal-fat studies, not speculative weight-loss trials. A pivotal 2010 placebo-controlled study showed a 10.9% reduction in visceral adipose tissue over 26 weeks abstract. A randomized JAMA study later confirmed reductions in both visceral and liver fat over 6 months. Those aren't small moves.

That evidence is why tesamorelin still shows up in body-composition discussions: the visceral-fat reduction is real in its intended population. It also explains why tesamorelin stands apart from more speculative approaches like AOD-9604. A 2024 efficacy and safety review confirmed tesamorelin as the only FDA-approved therapy for abdominal fat accumulation in people with HIV. That's a significant, rare distinction.

The routine that goes beyond the dose

The daily injection is only part of the picture. Both labels call for abdomen-site rotation, glucose evaluation, and IGF-1 monitoring, and they list active malignancy and pregnancy as contraindications label precautions. That means a real tesamorelin routine is not just the injection—it's confirming the formulation, confirming your clinical indication, and keeping the monitoring consistent with what the evidence supports.

• Confirm the formulation first: WR and SV have different strengths, diluents, storage rules, and injection volume-per-dose.
• Keep the goal specific: tesamorelin's label is for HIV-related excess abdominal fat, not general obesity management.
• Treat monitoring as part of the protocol: site rotation, glucose follow-up, and IGF-1 monitoring are part of the evidence-based routine.

Bottom line

If you searched tesamorelin dosage, you need two things. First: confirm which formulation—WR and SV are both once-daily injections, but they use different strengths and mixing routines. Second: confirm your indication. Tesamorelin is labeled for HIV-associated abdominal fat reduction, not general weight loss. That specificity is not a limitation. It's what makes the protocol clear and the evidence solid.